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Interstitial photodynamic therapy (IPDT) is a technique for applying photodynamic therapy (PDT) to internal tumours using light
delivered via fibres inserted percutaneously. This phase I–II study assessed the safety and efficacy of IPDT for patients with persistent
or recurrent head and neck cancer unsuitable for further treatment with surgery, radiotherapy or chemotherapy, recruited for ‘last
hope’ salvage treatment. Patients were sensitised with 0.15mgkg
 1 mTHPC (meso-tetrahydroxyphenyl chlorin) 4 days prior to light
delivery from fibres inserted directly into the target tumour (20J per site at 652nm) under image guidance. In all, 45 patients were
treated. Nine achieved a complete response. Five are alive and free of disease 10–60 months later. Symptomatic relief (mainly for
bleeding, pain or tumour debulking) was achieved in a further 24. The median survival (Kaplan–Meier) was 16 months for the 33
responders, but only 2 months for the 12 nonresponders. The only serious complication was a carotid blow out 2 weeks after PDT.
No loss of function was detected in nerves encased by treated tumours. Interstitial photodynamic therapy provides worthwhile
palliation with few complications and occasional long-term survivors for otherwise untreatable advanced head and neck cancers. It is a
treatment option worth adding to those available to integrated head and neck oncology teams.
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The treatment of head and neck cancer continues to pose a major
clinical challenge. Although some early cancers can be cured, the
overall survival rates have remained unchanged for several decades
(Black et al, 1997). In all, 30–40% of patients with head and neck
cancer have persistent or recurrent locoregional disease after
completion of definitive treatment. In the majority, surgical
salvage is either not feasible or carries a high risk of complications
(Watson and Ridge, 1998). Similarly, further radiotherapy is often
impossible as surrounding tissues will already have received the
maximum tolerable dose of ionising radiation (De Crevoisier et al,
1998; Stewart, 1999). Only a very small portion of these patients are
long-term survivors.
Photodynamic therapy (PDT) is a site-specific tumour treatment
involving the administration of a photosensitiser followed by focal
activation in the presence of oxygen using light of a wavelength
matched to an absorption peak of the photosensitiser (Dougherty
et al, 1998). For cancers of the oral cavity, the function and
appearance of the mouth can be preserved without sacrificing the
efficacy of tumour control (Fan et al, 1997; Hopper, 2000).
Photodynamic therapy does not have the cumulative toxicity
associated with ionising radiation and can be applied safely to
previously irradiated tissues. Thus, it has considerable potential
for patients with locally persistent or recurrent disease after
surgery or radiotherapy.
Photodynamic therapy is usually undertaken with external
illumination of the target tissue. Larger lesions in surgically
inaccessible sites can be treated with interstitial therapy, using
multiple laser fibres inserted directly into tumours through needles
positioned under image guidance (Bown et al, 2002). In this paper,
we report the first phase I–II study to assess the safety and efficacy
of interstitial PDT (IPDT) as a salvage treatment for recurrent head
and neck cancers.
MATERIALS AND METHODS
Patients
Patients with biopsy confirmed persistent or recurrent head and
neck cancers were recruited from the multidisciplinary oncology
clinic at the University College London Hospitals. These tumours
were either considered unresectable or the patients were not
suitable for further surgery. Some patients already had complica-
tions from prior radiotherapy and none were suitable for further
irradiation. All were regarded as having a poor prognosis. All
patients underwent either computerised tomography (CT) or
magnetic resonance imaging (MRI) to assess the extent of disease.
The experimental nature of the treatment was explained and
written consent was obtained. The study was approved by the
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lethics committee of the University College London Hospitals,
although during the course of the study, the photosensitising drug
used was approved by the European Medicines Evaluation Agency
for surface illumination PDT in this group of patients.
Interstitial photodynamic therapy
Patients were sensitised with 0.15mgkg
 1 intravenous meso-
tetrahydroxyphenyl chlorin (mTHPC, Foscan
s, Biolitec Pharma-
ceuticals Ltd, Germany) and were treated 4 days later. The light
source was a diode laser (Diomed Ltd, Cambridge, or Ceramoptec
Gmbh, Germany, wavelength 652nm) with the primary beam
feeding into a beam splitter to produce four treatment fibres (core
diameter 0.4mm, clean cut tip without diffuser). The power
delivered down each fibre was 100mW, checked with a power
metre prior to use. Needles (18G) were positioned transorally or
percutaneously into the tumours at approximately 1.5cm intervals.
Ultrasound, CT or MRI guidance was used for needle insertion into
deep-seated tumours, particularly for those thought to lie close to
vital structures such as the carotid artery, cervical vertebrae or the
skull. The fibres were passed through the needles using a flagging
system to ensure that the fibre tip was exposed to the tissues and
not still inside the needle. Up to four fibres were positioned at a
time and a pullback technique was used with 1cm steps to treat
thicker tumours. The energy applied at each treatment site was
20J. After administration of mTHPC, patients followed a regime of
controlled re-exposure to ambient light over a period of 2–3
weeks.
Assessment and follow-up
The results were assessed 4 weeks after PDT. Complete response
(CR): no evidence of disease; partial response (PR): 50% decrease
of the tumour volume; stable disease (SD): no change in tumour
size enough to describe as PR or PD; progressive disease (PD): an
increase of at least 25% in the size of measurable lesions or the
appearance of any new lesions. Tumour volume was estimated by
physical and radiographic measurements before and after PDT.
Most treatments were carried out with palliative intent and the
results assessed objectively and subjectively.
RESULTS
Between July 1997 and December 2002, 45 patients, 42 with
recurrent and three with persistent cancers, were treated with
salvage IPDT. Details of the patients and their management prior
to IPDT are summarised in Table 1. Tumour details are
summarised in Table 2.
Table 2 Tumour details
a
Tumour
location
No. of patients
(no response)
Tumour
location
No. of
patients (no
response)
Anterior tongue 8 (1) Tonsillar region 5
Buccal mucosa 2 Oropharyngeal wall 2
Floor of mouth 4 Maxillary sinus 3 (2)
Alveolar ridge 4 (2) Nasal cavity 3 (1)
Hard palate 3 (1) Nasopharynx 1
Tongue base 1 Parotid 2
Neck 6 (5) Thyroid 1
aIn all, 33 were squamous cell carcinomas and three were adenocystic carcinomas.
There was one each of: basal cell carcinoma (parotid gland), olfactory neuroblastoma,
follicular cell carcinoma, haemangiopericytoma, branchiogenic carcinoma, primitive
neuroectodermal tumour, malignant fibrous histiocytoma, osteosarcoma and alveolar
soft part sarcoma. Tumour staging at the time of PDT was: rT2:3, rT3:3, rT4:37,
rN2:1, rN3:1. The estimated median tumour volume for the entire series was 38cm
3
(range 8–224cm
3). The figures within parentheses indicate tumours that did not
respond to IPDT.
Figure 1 Alveolar soft part sarcoma in an 8-year-old girl. (A) Palate
viewed immediately before the first IPDT. A retractor (dark arrows) was
applied to the upper lip (UL) exposing the bulky tumour that occupied the
whole hard palate with extension to the soft palate and the right palatine
tonsil. Black shields (B) were used to protect the tongue (T) and normal
oral mucosa. White arrows indicate the endotracheal tube. (B) Palate
viewed 4 weeks after her second IPDT. A mirror was put on her tongue
and chin (C) to show the post-treatment condition. Dark arrows indicate
the lateral edge of the mirror. There was no visible tumour, although an
oronasal fistula (white arrows) had developed. A biopsy at this time
showed persistent tumour microscopically, but after a local excision and
radiotherapy, she became disease free and has remained well for 5 years.
Table 1 Patient details
a
Median age 58 years (range 8–84)
Sex
Male 28 (62 %)
Female 17 (38 %)
Primary treatment
Surgery 21 (47 %)
Radiation 41 (91 %)
External only 31
External and brachytherapy 3
Concurrent chemotherapy 7
Salvage treatment after recurrence 21 (47%)
PDT with external illumination 3
Surgery 13
Brachytherapy 3
Palliative chemotherapy 7
aMany primary and some salvage treatments prior to IPDT included more than one
therapeutic modality.
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lIn total, 67 treatments were performed on the 45 patients. The
laser fibres were inserted transorally, percutaneously or both in 36
(54%), 25 (37%) and 6 (9%) treatments, respectively. Of these, 30
patients (67%) received a single treatment; 10 patients (22%)
received two treatments, four patients (9%) received three and one
patient received five treatments. Of the treated tumours, 27% (12
of 45) were close to major structures deep in the neck (e.g. carotid
artery), another 20% (nine of 45) had invaded up under the base of
skull, while 16% (seven of 45) had compressed the trachea. The
responses were assessed at 1 month. Complete response was
achieved after eight treatments; PR was achieved after 43
treatments, one of which became a CR with additional treatment,
as described below, SD was noted after six treatments and PD after
10 treatments (including two who died less than a month after
PDT). The overall response rates for patients at 1 month after their
last PDT were: CR, nine of 45 (20%); PR, 24 of 45 (54%); SD, six of
45 (13%); PD six of 45 (13%).
Although the patients in this study had failed conventional
therapy, seven were treated with curative intent because of the
relatively early stage of recurrent disease. Four had a CR after
IPDT. Two others only had PR and subsequently died of their
disease 9 and 17 months later. A young girl with a 5cm alveolar
soft part sarcoma of the hard palate had a limited tumour resection
and full courses of ifosfamide, vincristine and actinomycin-D
before IPDT, but still had progressive disease. After two treatments
with IPDT, only microscopic tumour was detectable. After
radiotherapy and a further local resection she became disease free
and is now alive and well 5 years later (Figure 1). Four further
patients, who were treated initially with palliative intent, had a CR.
Of the nine patients who achieved disease-free status, five are still
alive and free of disease 10–60 months after PDT (Table 3).
A total of 38 patients were treated with palliative intent,
including the four who had a CR. Of the other 34, 21 were fed
through a gastrostomy and five also had a tracheostomy. One
patient had a tracheostomy without a gastrostomy. In all, 12 had
bulky tumours, but were able to maintain oral nutrition. In all but
five, the main clinical problem was the tumour bulk (median
48cm
3, range 12–224cm
3). Some had more than one dominant
symptom. It was not possible to improve swallowing or close the
tracheostomy in any of these individuals. Nevertheless, PDT
reduced the tumour bulk with subjective benefit for the patients in
18 of 29 cases. Bleeding was stopped in three of three, dyspnoea
was relived in one of two and brachial plexus compression was
relived in one of one, but pain was only helped in two of five cases.
Clinical benefit was achieved for 25 of the 40 dominant symptoms.
Magnetic resonance images of one patient before and after PDT to
reduce bleeding are shown in Figure 2. Of the 24 patients in this
group who achieved worthwhile palliation from PDT, eight
survived for more than a year (including two who are still alive,
24 and 31 months after PDT).
The 12 patients who did not respond to PDT (stable or
progressive disease) were treated mainly to attempt reduction of
the tumour bulk (median 56cm
3, range 20–224cm
3). The location
of these tumours is indicated in Table 2. The median survival of
this group was only 2 months (range 0.5–6 months). For the whole
group of 45 patients, the median survival (Kaplan–Meier) was 14
months (Figure 3). For the 33 patients responding to PDT, the
figure was 16 months. Patients with squamous carcinomas had a
slightly shorter survival compared with other pathologies (not
significant).
Eight patients had treatments in close proximity to the facial
nerve, 15 were close to the hypoglossal nerve and two were close to
the brachial plexus. The only neurological deficits prior to PDT
were in two hypoglossal nerves and one brachial plexus. After
PDT, there was no further loss of function in any of these nerves
and in the patient with a brachial plexus deficit, voluntary arm
movement improved after PDT.
Complications
The expected post-treatment pain and swelling subsided in 2–4
weeks. There was no treatment-related airway obstruction. The
only major treatment-related complication was a carotid blow out
2 weeks after PDT in a 33-year-old woman with recurrent neck
Table 3 Summary of complete responders and disease-free patients
Case
no.
Age at
IPDT
(years) Sex
Treatment
site Pathology
Stage
original/
recurrent
Previous
treatment
Time from
initial tx to
IPDT
(month)
Tumour
volume
(cm
3) prior
to PDT
Disease-free
time
(month)
Follow-up
time
(month) Outcome
1
52
M Neck SCC N3/N2 R, S 18 12 14 17 LR
2
57
F HP SCC T2/T4 R 30 32 NER 22 UD
3
60
M TB SCC T4/T4 CR, B 46 80 12 17 LR
4
82
F AR SCC T4/T2 S, S 5 8 NER 13 AW
5
21
F Tongue SCC T1/T3 S, S 24 12 26 32 LR
6
52
M FOM SCC T4/T3 S, R 5 10 NER 10 AW
7
59
M Tongue SCC T4/T4 CR 8 60 NER 28 AW
8
42
F Parotid ACC T4/T4 S, R 46 32 NER 15 AW
9
a
8
F HP ASPS T2B/T2B C, S 3 20 NER 60 AW
ACC: adenoid cystic carcinoma, AR: alveolar ridge, ASPS: alveolar soft part sarcoma, AW: alive and well, B: brachytherapy, C: chemotherapy, CR: chemoradiation, FOM: floor of
mouth, HP: hard palate, LR: died of local recurrence of disease, NER: no evidence of recurrence at the last follow-up, R: radiotherapy, S: surgery, SCC: squamous cell carcinoma,
TB: tongue base, tx: treatment, UD died of unrelated disease; IPDT¼interstitial photodynamic therapy; PDT¼photodynamic therapy.
aTwo IPDT treatments were performed
to debulk the tumour followed by radiotherapy and local excision for persistent microscopic disease. Since then, she has been free of disease.
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ldisease. On an MR scan taken 1 month prior to IPDT, the tumour
was judged to be close to, but not involving the carotid artery.
Post-mortem examination showed malignant cells along the intima
of the carotid artery implying tumour invasion. Skin photosensi-
tivity was noted in one patient who failed to comply with the
recommended regime for ambient light exposure.
DISCUSSION
Despite the advances in oncology during the last few decades, most
patients with recurrent head and neck cancer still succumb to their
disease in a relatively short period of time. The patients in this
study were all referred for ‘last hope’ salvage treatment, having
been considered unsuitable for further treatment with surgery,
radiotherapy or chemotherapy. Nevertheless, five patients (11%)
are alive and apparently free of disease 10–60 months later, and
the median survival time for the 33 patients (73%) who responded
to PDT was 16 months. The short survival of the 12 who did not
respond (median 2 months) probably reflects poor patient
selection. All these individuals had bulky tumours in areas close
to vital structures, which made it difficult to deliver an appropriate
light dose to all relevant sites. The most difficult area was the
neck. After the carotid blow out (which occurred early in the
study), extra care was taken with tumours close to the carotid
artery, but this led to a lack of response in five out of six tumours
Figure 2 Magnetic resonance images of a maxillary cancer in a 76-year-old man with recurrent episodes of massive nasal bleeding requiring transfusion.
(A) T2-weighted MRI before IPDT, showing a tumour in the right maxillary antrum and periorbital invasion. (B) T1-weighted MRI during treatment showing
the position of the MR compatible needles prior to insertion of laser fibers. The needles appear as small, dark (low signal intensity) areas within the tumour
mass. (C) T2-weighted MRI 6 weeks after treatment demonstrating a dramatic reduction of tumour bulk. Nasal bleeding stopped after IPDT and the patient
lived for a further 19 months.
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ltreated in this region. If there is any suspicion that tumours have
invaded the carotid artery, PDT is probably not an appropriate
treatment.
Damage to cranial nerves and major blood vessels during
salvage surgery or radiotherapy is difficult to prevent and greatly
reduces the patients’ quality of life. In the present study, the
treated tumour encased or was in close proximity to important
nerves in 24 patients, but no loss of function was detected and in
one case (brachial plexus compression), nerve function improved
after PDT. Thus anecdotally, nerves seem to tolerate PDT well.
This conclusion is supported by a recent experimental study
looking at the effect of PDT with mTHPC on normal arteries and
nerves (Ku ¨bler et al, 2003). This is an aspect that should be studied
in further detail, as it is potentially a major attraction of PDT.
These unfortunate patients often have serious cosmetic and
functional deficiencies due to nerve damage after surgery or
radiotherapy, and if this could be avoided, it would be an
important step forward in the management of such cases. There is
also good experimental evidence that the risk of thrombosis or
rupture of normal arteries after PDT is minimal, due to
preservation of elastin and collagen fibres (Grant et al, 1995).
Better imaging should reduce the risk of treating arteries invaded
by tumour. The carotid blow-out was our only serious complica-
tion. The willingness of patients to undergo repeat treatments
showed that the technique was well tolerated.
Our results compare favourably with other therapeutic options.
Salvage surgery is rarely curative and carries a 20–40% risk of
serious complications (Marcial et al, 1980; Rate et al, 1991).
Similarly, many different salvage radiotherapy regimens have been
used, including external beam, interstitial ‘high-dose-rate’ or ‘low-
dose-rate’ brachytherapy (De Crevoisier et al, 1998; Puthawala et al,
2001; Glatzel et al, 2002). Although 20–30% of patients may
survive for 2 years, moderate to severe complications (including
carotid blow-out) have been reported in 30–40% of cases.
Chemotherapy for these recurrent cancers has a response rate of
no more than 10–30% with a median survival of about 6 months
(Clavel et al, 1994). Newer drugs have not improved the response
rates significantly from those seen with traditional cisplatin-based
chemotherapy (Forastiere et al, 1998).
Two of the three sarcomas treated in this study responded
remarkably well. The young girl with a sarcoma of the palate is free
of disease at 5 years and the older patient with a skull base
osteosarcoma had good relief from his headache. The third patient,
a boy of 15, did not respond and died a few weeks after treatment.
PDT may be able to play an important role in the management of
these rare tumours, especially those occurring in surgically
inaccessible sites, as the response to chemotherapy and radio-
therapy is not always good (Casanova et al, 2000).
Recurrent head and neck cancers are difficult to treat because of
the complex regional anatomy and close proximity to vital
structures. This study shows that IPDT can be an effective salvage
measure for these unfortunate patients. It is minimally invasive,
effective for carcinomas and sarcomas and can be used in patients
who are unfit for further radiotherapy or surgery. It is a
therapeutic option that is likely to become a useful addition to
the armamentarium of the integrated head and neck oncology
team for late-stage disease.
REFERENCES
Black RJ, Bray F, Ferlay J, Parkin DM (1997) Cancer Incidence and Morality
in the European Union: Cancer Registry Data and Estimates of National
Incidence for 1990. Eur J Cancer 33: 1075–1107
Bown SG, Rogowska AZ, Whitelaw DE, Lees WR, Lovat LB, Ripley P, Jones
L, Wyld P, Gillams A, Hatfield AWR (2002) Photodynamic therapy for
cancer of the pancreas. Gut 50: 549–557
Casanova M, Ferrari A, Bisogno G, Cecchetto G, Basso E, De B, Indolfi P,
Fossati B, Carli M (2000) Alveolar soft part sarcoma in children and
adolescents: a report from the Soft-Tissue Sarcoma Italian Cooperative
Group. Ann Oncol 11: 1445–1449
Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de M, Schornagel JH,
Tueni EA, Verweij J, Wildiers J, Clerico M (1994) Randomized
comparison of cisplatin, methotrexate, bleomycin and vincristine
(CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in
recurrent or metastatic squamous cell carcinoma of the head and neck. A
phase III study of the EORTC Head and Neck Cancer Cooperative Group.
Ann Oncol 5: 521–526
De Crevoisier R, Bourhis J, Domenge C, Wibault P, Koscielny S, Lusinchi A,
Mamelle G, Janot F, Julieron M, Leridant AM, Marandas P, Armand JP,
Schwaab G, Luboinski B, Eschwege F (1998) Full-dose reirradiation for
unresectable head and neck carcinoma: experience at the Gustave–
Roussy Institute in a series of 169 patients. J Clin Oncol 16: 3556–3562
Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M,
Moan J, Peng Q (1998) Photodynamic therapy. JNCI Cancer Spectrum 90:
889–905
Fan K, Hopper C, Speight PM, Buonaccorsi GA, Bown SG (1997)
Photodynamic therapy using mTHPC for malignant disease in the oral
cavity. Int J Cancer 73: 25–32
Forastiere AA, Shank D, Neuberg D, Taylor SG, DeConti RC, Adams G
(1998) Final report of a phase II evaluation of paclitaxel in patients
with advanced squamous cell carcinoma of the head and neck: an
Eastern Cooperative Oncology Group trial (PA390). Cancer 82:
2270–2274
Glatzel M, Buntzel J, Schroder D, Kuttner K, Frohlich D (2002) High-dose-
rate brachytherapy in the treatment of recurrent and residual head and
neck cancer. Laryngoscope 112: 1366–1371
Grant WE, Buonaccorsi G, Speight PM, MacRobert AJ, Hopper C, Bown SG
(1995) The effect of photodynamic therapy on the mechanical integrity of
normal rabbit carotid arteries. Laryngoscope 105: 867–871
Hopper C (2000) Photodynamic therapy: a clinical reality in the treatment
of cancer. Lancet Oncol 1: 212–219
Ku ¨bler AC, Stenzel W, Ru ¨hling M, Meul B, Fischer J-H (2003) Experimental
evaluation of possible side effects of intra-operative photodynamic
therapy on rabbitblood vessels and nerves. Lasers Surg Med 33(4): 247–
255
Marcial VA, Hanley JA, Ydrach A, Vallecillo LA (1980) Tolerance of surgery
after radical radiotherapy of carcinoma of the oropharynx. Cancer 46:
1910–1912
Puthawala A, Nisar S, Gamie S, Chen YJ, Londrc A, Nixon V (2001)
Interstitial low-dose-rate brachytherapy as a salvage treatment for
1.00
0.75
0.50
P
e
r
c
e
n
t
a
g
e
0.25
0
01 0
Time (months)
20 30 40 50 60
Figure 3 Overall survival (Kaplan–Meier curves).
Interstitial PDT for recurrent head and neck cancer
P-J Lou et al
445
British Journal of Cancer (2004) 91(3), 441–446 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lrecurrent head-and-neck cancers: long-term results. Int J Radiat Oncol
Biol Phys 51: 354–362
Rate WR, Garrett P, Hamaker R, Singer M, Pugh N, Ross D, Haerr R,
Charles G (1991) Intraoperative radiation therapy for recurrent head and
neck cancer. Cancer 67: 2738–2740
Stewart FA (1999) Re-treatment after full-course radiotherapy: is it a viable
option? Acta Oncol 38: 855–862
Watson JC, Ridge JA (1998) Surgical management of local and regional
recurrent head and neck squamous cell carcinoma. Curr Opin Oncol 10:
207–212
Interstitial PDT for recurrent head and neck cancer
P-J Lou et al
446
British Journal of Cancer (2004) 91(3), 441–446 & 2004 Cancer Research UK
C
l
i
n
i
c
a
l